313 related articles for article (PubMed ID: 28360348)
1. Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.
Kraehling JR; Sessa WC
Circ Res; 2017 Mar; 120(7):1174-1182. PubMed ID: 28360348
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
3. Vascular nitric oxide: Beyond eNOS.
Zhao Y; Vanhoutte PM; Leung SW
J Pharmacol Sci; 2015 Oct; 129(2):83-94. PubMed ID: 26499181
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
[TBL] [Abstract][Full Text] [Related]
5. Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO.
Lakshminarayanan S; Antonetti DA; Gardner TW; Tarbell JM
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4256-61. PubMed ID: 11095623
[TBL] [Abstract][Full Text] [Related]
6. Phenylephrine activates eNOS Ser 1177 phosphorylation and nitric oxide signaling in renal hypertensive rat aorta.
Silva BR; Pernomian L; Grando MD; Bendhack LM
Eur J Pharmacol; 2014 Sep; 738():192-9. PubMed ID: 24886887
[TBL] [Abstract][Full Text] [Related]
7. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
[TBL] [Abstract][Full Text] [Related]
8. Incubation of porcine iris-ciliary bodies to study the mechanisms by which nitric oxide donors lower intraocular pressure.
Kotikoski H; Kankuri E; Vapaatalo H
Med Sci Monit; 2003 Jan; 9(1):BR1-7. PubMed ID: 12552230
[TBL] [Abstract][Full Text] [Related]
9. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.
Hussain MB; Hobbs AJ; MacAllister RJ
Br J Pharmacol; 1999 Nov; 128(5):1082-8. PubMed ID: 10556946
[TBL] [Abstract][Full Text] [Related]
10. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters.
Greenberg SS; Cantor E; Ho E; Walega M
J Pharmacol Exp Ther; 1991 Sep; 258(3):1061-71. PubMed ID: 1679847
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide and the vascular endothelium.
Moncada S; Higgs EA
Handb Exp Pharmacol; 2006; (176 Pt 1):213-54. PubMed ID: 16999221
[TBL] [Abstract][Full Text] [Related]
12. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells.
Kroll J; Waltenberger J
Biochem Biophys Res Commun; 1999 Nov; 265(3):636-9. PubMed ID: 10600473
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase alpha1beta1-impact on inflammation.
Kajiya K; Huggenberger R; Drinnenberg I; Ma B; Detmar M
FASEB J; 2008 Feb; 22(2):530-7. PubMed ID: 17855621
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.
Ghalayini IF
Int J Impot Res; 2004 Dec; 16(6):459-69. PubMed ID: 15229623
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A suppresses arterial vasoconstriction by regulating calcium sensitization and the endothelium-dependent endothelial nitric oxide synthase/soluble guanylyl cyclase/cyclic guanosine monophosphate pathway: An
Hu L; Feng Y; Liu W; Jin L; Nie Z
Exp Biol Med (Maywood); 2019 Nov; 244(16):1475-1484. PubMed ID: 31547684
[TBL] [Abstract][Full Text] [Related]
16. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide decreases the expression of endothelin-converting enzyme-1 through mRNA destabilization.
Raoch V; Rodríguez-Pascual F; López-Martínez V; Medrano-Andrés D; Rodríguez-Puyol M; Lamas S; Rodríguez-Puyol D; López-Ongil S
Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2577-85. PubMed ID: 21852564
[TBL] [Abstract][Full Text] [Related]
18. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome.
Samlowski WE; Kondapaneni M; Tharkar S; McGregor JR; Laubach VE; Salvemini D
J Immunother; 2011 Jun; 34(5):419-27. PubMed ID: 21577143
[TBL] [Abstract][Full Text] [Related]
19. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
20. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
